VALT-T -0.8 MART-T -0.57 VIDY-T 0.04 RPRX-Q 0.35 NCSM-Q 1.61 HRTG-N 1.36 BA-N 6.14
Kevin Vandermeer, B.Comm, CFA

Kevin Vandermeer, B.Comm, CFA

Vice President and Portfolio Manager at AIC Limited

Member since: Mar '05 · 6 Opinions

UnlockRating

Rating Card

premium

Unlock Expert's Rating and Top Picks Portfolio

Curated by Michael O'Reilly since 2020
1550+ opinions with 4.81 rating (one of the best performing expert)

Latest Top Picks

Unlock Kevin's portfolio

Stock Opinions by Kevin Vandermeer, B.Comm, CFA

BUY

Novartis AG(NVS-N)

Mar 11, 2005
We really like it. One of the few pharma companies that have a generics division embedded in it. They continue to move in the generics area because they see growth in that sector.
Kevin Vandermeer, B.Comm, CFAKevin Vandermeer, B.Comm, CFA
Owned
Unlock Rating
$49.020

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Boston Scientific Corp(BSX-N)

Mar 11, 2005
"We really like Boston [Scientific]" Thinks they have a better product then the competitor. Had a series of recalls, but have been able to gain back the marketshare. But the stock didn't recover as well. So is now undervalued.
Kevin Vandermeer, B.Comm, CFAKevin Vandermeer, B.Comm, CFA
Owned
Unlock Rating
$30.000

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Valeant Pharmaceuticals(VRX-T)

Mar 11, 2005
Reported earlier this week and results were better then expected. Has reservations about the company. If you really want it, wait and watch.
Kevin Vandermeer, B.Comm, CFAKevin Vandermeer, B.Comm, CFA
No
Unlock Rating
$20.290

Stock price when the opinion was issued

Healthcare
DON'T BUY

Amgen Inc.(AMGN-Q)

Mar 11, 2005
Majority of money is from 3 products. Want's more diversificaion. Good balance sheet though.
Kevin Vandermeer, B.Comm, CFAKevin Vandermeer, B.Comm, CFA
No
Unlock Rating
$59.810

Stock price when the opinion was issued

biotechnology pharmaceutical
WATCH

Stryker Corp.(SYK-N)

Mar 11, 2005
Unbelieable business run by smart guys. Stable business, great stock for long term.
Kevin Vandermeer, B.Comm, CFAKevin Vandermeer, B.Comm, CFA
No
Unlock Rating
$47.430

Stock price when the opinion was issued

biotechnology pharmaceutical
TRADE

Angiotech Pharmaceuticals(ANP-T)

Mar 11, 2005
Technology is superior then Boston Scientific, and Boston markets for them. (for their main product). Would rather buy Boston, because it is more diversified, and slightly cheaper.
Kevin Vandermeer, B.Comm, CFAKevin Vandermeer, B.Comm, CFA
No
Unlock Rating
$18.720

Stock price when the opinion was issued

biotechnology pharmaceutical
Showing 1 to 6 of 6 entries
  • «
  • ‹
  • 1
  • ›
  • »

Build our watch list

Sign in to track investments
you care about

Latest Buy Signals

CMNY-T 0.01$50.09
HEQL-T 0.44$27
DXP-T 0.14$23.24
ZMMK-T 0.005$49.895
PYF-T 0.04$17.39

Today's Top Picks

VALT-T -0.8$40.6
MART-T -0.57$22.9
VIDY-T 0.04$35.23
RPRX-Q 0.35$33.1
NCSM-Q 1.61$32.71

Popular Articles

Latest Sell Signals

HPYT-T -0.105$9.175
RHT-X 0.005$0.215
GOOG-Q 2.95$155.75
GOOG-Q 2.95$155.75
T-T 0.03$20.8

Most Recent Experts

Daniel Straus

Daniel Straus

National Bank Financial

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

Stockchase Insights

Stockchase Insights

5i Research

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica